RecruitingPhase 1NCT07612813

A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adult Participants

Sponsor

AstraZeneca

Enrollment

18 participants

Start Date

Jun 29, 2026

Study Type

INTERVENTIONAL

Conditions

Staphylococcus Aureus Bloodstream Infection

Summary

The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AZD7760 and Placebo for people with staphylococcus aureus bloodstream infection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAZD7760

Participants will receive AZD7760 via IV infusion.

OTHERPlacebo

Participants will receive matching placebo via IV infusion.

Locations(1)

Research Site

Sumida-ku, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07612813

Related Trials

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT066504881 location

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT066505011 location